Abstract

Mutations in the DNA/RNA binding proteins TDP-43 and FUS are associated with Amyotrophic Lateral Sclerosis and Frontotemporal Lobar Degeneration. Intracellular accumulations of wild type TDP-43 and FUS are observed in a growing number of late-onset diseases suggesting that TDP-43 and FUS proteinopathies may contribute to multiple neurodegenerative diseases. To better understand the mechanisms of TDP-43 and FUS toxicity we have created transgenic Caenorhabditis elegans strains that express full-length, untagged human TDP-43 and FUS in the worm's GABAergic motor neurons. Transgenic worms expressing mutant TDP-43 and FUS display adult-onset, age-dependent loss of motility, progressive paralysis and neuronal degeneration that is distinct from wild type alleles. Additionally, mutant TDP-43 and FUS proteins are highly insoluble while wild type proteins remain soluble suggesting that protein misfolding may contribute to toxicity. Populations of mutant TDP-43 and FUS transgenics grown on solid media become paralyzed over 7 to 12 days. We have developed a liquid culture assay where the paralysis phenotype evolves over several hours. We introduce C. elegans transgenics for mutant TDP-43 and FUS motor neuron toxicity that may be used for rapid genetic and pharmacological suppressor screening.

Highlights

  • Amyotrophic Lateral Sclerosis (ALS) is a late-onset progressive disease affecting motor neurons causing fatal paralysis [1,2]

  • We introduce a genetically tractable platform to investigate motor neuron toxicity caused by mutant TAR DNA-binding protein-43 (TDP-43) and FUS that can be used for suppressor screening

  • Paralysis was agedependent and occurred at higher rate for mTDP-43 and mFUS worms compared to wtTDP-43 and wtFUS transgenics (Figures 3 A, B)

Read more

Summary

Introduction

Amyotrophic Lateral Sclerosis (ALS) is a late-onset progressive disease affecting motor neurons causing fatal paralysis [1,2]. Dominant mutations in SOD1 (copper/zinc superoxide dismutase 1) account for ,20% of familial ALS cases and ,1% of sporadic cases [1]. The recent discovery of mutations in TAR DNA-binding protein-43 (TDP-43) and Fused in sarcoma (FUS, named TLS) in both familial ALS and frontotemporal dementia (FTD) has shifted research into disease mechanisms and potential therapeutics [3,4,5,6,7,8,9]. TDP-43 and FUS are evolutionarily conserved DNA/RNA binding proteins that shuttle between the nucleus and cytoplasm having multiple roles including DNA transcription and RNA processing [3,9,10,11,12]. As of there is no consensus whether mutant TDP-43 and FUS employ a loss-of-function, a gain-of-function, or both in motor neuron cell death

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.